Here you can find details of our previous annual meetings
2024 Annual Meeting
Focussing on update on ECP in low body weight patients, non erythrodermic Sezary, E-CLAD trial, and ECP, EV and paediatric aGvHD.
2023 Annual Meeting
Focussing on improving overall survival in aGvHD by applying ECP, the dual role of ROCK2 inhibitors and ECP in treating GvHD, vascular access, vascular Issues + audit, E-CLAD trial update and progress, and extracellular vesicles in ECP response.
2022 Annual Meeting
Focussing on combination treatment for GvHD, running an ECP service, audit of ECP treatment cycles, and ECP in combination with new treatment protocols in acute and chronic GvHD.
2021 Annual Meeting
(virtual)
Focussing on first line usage and treatment paradigms, immune monitoring assay for ECP treatment optimisation after heart transplantation, covid and ECP audit, anticoagulant audit, and dendritic cells and GvHD.
2020 Annual Meeting
(virtual)
Focussing on ECP usage in combinational approaches, Extracorporeal Photopheresis 2020 Update, and a practical guide to patient management.
2019 Annual Meeting
Focussing on role of ECP in cardiac transplantation, CP experience in lung transplant in the UK, cGVHD national audit, Qol with ECP in CTCL, and mechanistic insights into mode of action of ECP.
2018 Annual Meeting
Focussing on Cutaneous chronic GvHD and role of biomarkers, UK paediatric ECP audit, PROCLIPI study in CTCL, role of physiotherapy in chronic GvHD, and role of allogeneic BMT in management of advanced CTCL.
2017 Annual Meeting
Focussing on national CTCL audit, new NIH classification for GvHD, specialised commissioning, POSTAGE study update, and update on national registry.
The UK Photopheresis Society 